Skip to main content
AmigoFish

Rewriting the Playbook for Stargardt Disease with Atsena Therapeutics' Shannon Boye, Ph.D.

From Cell & Gene: The Podcast · · 18 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

We love to hear from our listeners. Send us a message. (https://www.buzzsprout.com/1810482/fan_mail/new)

Episode 134 of Cell & Gene: The Podcast features Host Erin Harris' discussion with Shannon Boye, PhD, Founder and CSO of Atsena Therapeutics. Dr. Boye shares how the company is approaching Stargardt disease with a differentiated gene therapy strategy built around delivery, dual-vector design, and a disciplined go/no-go framework. Their conversation also explores what Atsena’s broader clinical experience is teaching the team as it advances new programs and works toward the clinic.

Subscribe to the podcast! Apple (https://podcasts.apple.com/us/podcast/cell-gene-the-podcast/id1574496063) | Spotify (https://open.spotify.com/show/78NSjRuHndVhI5VHWWAMya) | YouTube (https://music.youtube.com/playlist?list=PLFXsCNKV78rWyuxay7hXQFo0rVyAXAdwX)

Visit my website: Cell & Gene (https://www.cellandgene.com/)

Connect with me on LinkedIn (https://www.linkedin.com/in/erinharris/)

Back to Cell & Gene: The Podcast · Report a problem